This “Huntington’s disease - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Huntington’s disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Huntington’s disease is inherited as an autosomal dominant trait. It is caused by a single defective gene on chromosome 4 - one of the 23 human chromosomes that carry a person’s entire genetic code. The defective gene codes the blueprint for a protein called huntingtin. This protein's normal function isn't yet known, but it's called "huntingtin" because scientists identified its defective form as the cause of Huntington's disease. Defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression and other mood changes. The huntingtin gene defect involves extra repeats of one specific chemical code in one small section of chromosome 4. The normal huntingtin gene includes 17 to 20 repetitions of this code among its total of more than 3,100 codes. The defect that causes Huntington's disease includes 40 or more repeats.
Symptoms of Huntington's disease usually develop between ages 30 and 50, but they can appear as early as age 2 or as late as 80. It is characterized by rapid uncontrollable muscle movements such as tics or muscle jerks (choreiform movements or chorea). This disorder causes a loss of coordination and personality changes. As the disease progresses, the ability to speak may be impaired, memory may fade, and the involuntary jerky muscle movements (chorea) become more severe.
The diagnosis of Huntington's disease may be confirmed by a thorough clinical evaluation, detailed patient history, and a variety of specialized tests. Tests include: Blood test, Genetic testing, and Imaging tests. Genetic testing determines if an individual have a mutation on the HTT gene. Specialized x-ray studies such as computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or electroencephalography (EEG) may help confirm the diagnosis of Huntington's Disease. During CT scanning, a computer and x-rays are used to create a file showing cross-sectional images of the brain. During MRI, a magnetic field and radio waves are used to create cross-sectional images of the brain. During an EEG, an instrument records electrical activity of the brain.
"Huntington’s disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Huntington’s disease pipeline landscape is provided which includes the disease overview and Huntington’s disease treatment guidelines. The assessment part of the report embraces, in depth Huntington’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
Huntington’s disease: Understanding
Huntington’s disease: Overview
Huntington’s disease is a genetic, progressive, neurodegenerative disorder characterized by the gradual development of involuntary muscle movements affecting the hands, feet, face, and trunk and progressive deterioration of cognitive processes and memory (dementia). This disease causes changes in the central area of the brain, which affect movement, mood and thinking skills.Huntington’s disease is inherited as an autosomal dominant trait. It is caused by a single defective gene on chromosome 4 - one of the 23 human chromosomes that carry a person’s entire genetic code. The defective gene codes the blueprint for a protein called huntingtin. This protein's normal function isn't yet known, but it's called "huntingtin" because scientists identified its defective form as the cause of Huntington's disease. Defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression and other mood changes. The huntingtin gene defect involves extra repeats of one specific chemical code in one small section of chromosome 4. The normal huntingtin gene includes 17 to 20 repetitions of this code among its total of more than 3,100 codes. The defect that causes Huntington's disease includes 40 or more repeats.
Symptoms of Huntington's disease usually develop between ages 30 and 50, but they can appear as early as age 2 or as late as 80. It is characterized by rapid uncontrollable muscle movements such as tics or muscle jerks (choreiform movements or chorea). This disorder causes a loss of coordination and personality changes. As the disease progresses, the ability to speak may be impaired, memory may fade, and the involuntary jerky muscle movements (chorea) become more severe.
The diagnosis of Huntington's disease may be confirmed by a thorough clinical evaluation, detailed patient history, and a variety of specialized tests. Tests include: Blood test, Genetic testing, and Imaging tests. Genetic testing determines if an individual have a mutation on the HTT gene. Specialized x-ray studies such as computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or electroencephalography (EEG) may help confirm the diagnosis of Huntington's Disease. During CT scanning, a computer and x-rays are used to create a file showing cross-sectional images of the brain. During MRI, a magnetic field and radio waves are used to create cross-sectional images of the brain. During an EEG, an instrument records electrical activity of the brain.
"Huntington’s disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Huntington’s disease pipeline landscape is provided which includes the disease overview and Huntington’s disease treatment guidelines. The assessment part of the report embraces, in depth Huntington’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Huntington’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Huntington’s disease.Huntington’s disease Emerging Drugs Chapters
This segment of the Huntington’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Huntington’s disease Emerging Drugs
Pridopidine: Prilenia Therapeutics
Pridopidine is an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day. Multiple clinical studies have been conducted providing important understanding about pridopidine’s safety, mechanism of action, and efficacy. Activation of the S1R by pridopidine enhances the clearance of toxic proteins, enhances energy production, and reduces cellular stress and inflammation. Studies in animal models and human cells show that pridopidine prevents neuronal cell death, and strengthens and enhances the connections between neurons. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Huntington’s disease.ANX005: Annexon
ANX005 is a humanized IgG4 monoclonal antibody that binds with high affinity to the complement C1q protein and inhibits initiation of the classical complement cascade. Given by intravenous infusion, the antibody is in development to treat autoimmune and neurodegenerative disorders. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Huntington’s disease.LPM3770164: Luye Pharma
LPM3770164 is a drug candidate being developed by Shandong Luye Pharmaceutical Co., Ltd. It is a VMAT2 inhibitor, which is a type of medication that targets the vesicular monoamine transporter 2 (VMAT2) protein. Currently, the drug is in the Phase I stage of development to treat Huntington’s disease.Huntington’s disease: Therapeutic Assessment
This segment of the report provides insights about the different Huntington’s disease drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Huntington’s disease
- There are approx. 20+ key companies which are developing the therapies for Huntington’s disease. The companies which have their Huntington’s disease drug candidates in the most advanced stage, i.e. Phase III include, Prilenia Therapeutics.
Phases
This report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Huntington’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Huntington’s disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Huntington’s disease therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Huntington’s disease drugs.Huntington’s disease Report Insights
- Huntington’s disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Huntington’s disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Huntington’s disease drugs?
- How many Huntington’s disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Huntington’s disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Huntington’s disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Huntington’s disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Prilenia Therapeutics
- Annexon
- Luye Pharma
- Sage Therapeutics
- Wave Life Sciences
- UniQure Biopharma
- Medesis Pharma
- Spark therapeutics
- ExoRNA Bioscience
Key Products
- Pridopidine
- ANX005
- LPM3770164
- SAGE-718
- WVE003
- AMT 130
- Nano P42T
- Huntington’s Disease therapy
- ER2001
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive SummaryHuntington’s disease- Analytical PerspectiveHuntington’s disease Key CompaniesHuntington’s disease Key ProductsHuntington’s disease- Unmet NeedsHuntington’s disease- Market Drivers and BarriersHuntington’s disease- Future Perspectives and ConclusionHuntington’s disease Analyst ViewsHuntington’s disease Key CompaniesAppendix
Huntington’s disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Pridopidine: Prilenia Therapeutics
Mid Stage Products (Phase II)
ANX005: Annexon
Early Stage Products (Phase I)
LPM3770164: Luye Pharma
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Prilenia Therapeutics
- Annexon
- Luye Pharma
- Sage Therapeutics
- Wave Life Sciences
- UniQure Biopharma
- Medesis Pharma
- Spark therapeutics
- ExoRNA Bioscience
